CL2022000217A1 - enzyme inhibitors - Google Patents

enzyme inhibitors

Info

Publication number
CL2022000217A1
CL2022000217A1 CL2022000217A CL2022000217A CL2022000217A1 CL 2022000217 A1 CL2022000217 A1 CL 2022000217A1 CL 2022000217 A CL2022000217 A CL 2022000217A CL 2022000217 A CL2022000217 A CL 2022000217A CL 2022000217 A1 CL2022000217 A1 CL 2022000217A1
Authority
CL
Chile
Prior art keywords
enzyme inhibitors
compounds
therapy
compositions
formula
Prior art date
Application number
CL2022000217A
Other languages
Spanish (es)
Inventor
Rebecca Louise Davie
Hannah Joy Edwards
David Michael Evans
Simon Teanby Hodgson
Alun John Smith
Emanuela Gancia
Andrew Peter Cridland
Erica Lee Goldsmith
Paul Stuart Hinchliffe
Karamjit Singh Jandu
Original Assignee
Kalvista Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalvista Pharmaceuticals Ltd filed Critical Kalvista Pharmaceuticals Ltd
Priority to CL2022000217A priority Critical patent/CL2022000217A1/en
Publication of CL2022000217A1 publication Critical patent/CL2022000217A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona compuestos de Fórmula (I); composiciones que comprenden dichos compuestos; el uso de dichos compuestos en terapia; y métodos para tratar pacientes con dichos compuestos; en donde A, B y n son como se definen en el presente documento.The present invention provides compounds of Formula (I); compositions comprising said compounds; the use of said compounds in therapy; and methods for treating patients with said compounds; where A, B and n are as defined herein.

CL2022000217A 2022-01-27 2022-01-27 enzyme inhibitors CL2022000217A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CL2022000217A CL2022000217A1 (en) 2022-01-27 2022-01-27 enzyme inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CL2022000217A CL2022000217A1 (en) 2022-01-27 2022-01-27 enzyme inhibitors

Publications (1)

Publication Number Publication Date
CL2022000217A1 true CL2022000217A1 (en) 2022-11-04

Family

ID=84282981

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022000217A CL2022000217A1 (en) 2022-01-27 2022-01-27 enzyme inhibitors

Country Status (1)

Country Link
CL (1) CL2022000217A1 (en)

Similar Documents

Publication Publication Date Title
CO2022000481A2 (en) enzyme inhibitors
ECSP22087539A (en) FUSIONED TRICYCLIC KRAS INHIBITORS
ECSP18094983A (en) PIRAZOLE DERIVATIVES AS INHIBITORS OF PLASMA CALICREIN
CR20190252A (en) 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant idh1 and idh2 inhibitors
BR112021018303A2 (en) Novel small molecule inhibitors of tead transcription factors
CO2022010330A2 (en) Gamma-Hydroxybutyrate (GHB) Dosage
BR112017024331A2 (en) compound, pharmaceutical composition, method of treating a human, methods for inhibiting the activity of an acid1 protein, the growth or proliferation of cancer cells, and immunosuppression in a patient, and treating a disease, and, using a compound
ECSP23007180A (en) TRICYCLIC UREA COMPOUNDS AS JAK2 INHIBITORS V617F
CO2022000422A2 (en) enzyme inhibitors
CL2022000093A1 (en) Imidazopyrimidines as eed inhibitors and their use
CO2022000270A2 (en) enzyme inhibitors
CO2022000266A2 (en) enzyme inhibitors
CO2024001285A2 (en) Tricyclic compounds as kras inhibitors
CL2023000061A1 (en) Macrocycles and their use
CO2023013469A2 (en) Phosphorus derivatives as new sos1 inhibitors
CO2022013055A2 (en) Tafoxiparin for the treatment of pre-eclampsia
ECSP22098041A (en) ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE OF THESE
CL2023001637A1 (en) Jak1 pathway inhibitors for the treatment of vitiligo.
CO2023012342A2 (en) enzyme inhibitors
CO2023008475A2 (en) enzyme inhibitors
CL2022000217A1 (en) enzyme inhibitors
CO2022014199A2 (en) Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus, including covid-19
CO2021014351A2 (en) Quinoline derivatives and their use for cancer treatment
BR112022022515A2 (en) METHYLTHIONIUM COMPOUNDS FOR USE IN THE TREATMENT OF COVID-19
CL2022000218A1 (en) enzyme inhibitors